--- title: "Semax Deep Research Review" slug: "semax" type: "research" url: "https://peptidesciencethailand.com/research/semax" lastReviewed: "2026-03-31" overallScore: "1.5/5" verdict: "Preclinical-rich, clinically limited" description: "Is Semax a proven focus and recovery peptide? 18 studies on BDNF, stroke, and cognition graded — mostly animal evidence. Honest 1.5/5 verdict inside." --- # Semax — Deep Research Review **Full name:** ACTH(4-7)-Pro-Gly-Pro (Heptapeptide) **Sequence:** Met-Glu-His-Phe-Pro-Gly-Pro **Molecular weight:** ~813 Da **Overall evidence score:** 1.5/5 **Verdict:** Preclinical-rich, clinically limited ## Executive Summary Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from an ACTH fragment, developed and used as a neuroactive intranasal drug in Russia. The strongest signal in peer-reviewed literature is not limitless nootropic enhancement, but context-dependent neurobiological modulation (neurotrophin expression, monoaminergic signalling, inflammatory gene programmes) most consistent in acute injury/stress paradigms and stroke models in animals. Human evidence exists but centres on small, older clinical studies (often Russian-language) with limited endpoints, plus a few neuroimaging experiments in healthy volunteers. This is far from the multi-centre, preregistered, blinded evidence base that social media implies. The U.S. FDA specifically identifies Semax as a Category 2 bulk substance with potential safety risks for compounding, citing immunogenicity, aggregation, peptide impurities, and limited safety information. ## Editorial Position Semax is interesting and partially evidenced rather than proven and generalisable. The preclinical stroke/neuroprotection dossier is meaningful, but human-grade efficacy and safety certainty remain insufficient for broad claims. Regulatory signals materially raise the bar for how cautiously it should be discussed. ## What It Is Semax is commonly described in the peer-reviewed literature as an ACTH-fragment analogue (ACTH(4-7)PGP / ACTH(4-10) analogue) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The most prominent translational focus is neuroprotection and rehabilitation adjunct use in ischaemic stroke and other CNS conditions, with animal work spanning focal and transient MCA occlusion models, behavioural learning paradigms, and stress-related phenotypes. ## Mechanisms ### Neurotrophin modulation (BDNF/NGF) *Verdict:* Strongest mechanistic evidence Semax has evidence for saturable, calcium-dependent binding sites in rat basal forebrain membranes (KD ~2.4 nM, BMAX ~33.5 fmol/mg protein). In vitro, Semax increased NGF and BDNF mRNA in glial cultures (~8-fold BDNF, ~5-fold NGF at ~30 minutes). In vivo, single intranasal dosing (50 ug/kg) produced rapid, region-specific changes: BDNF protein increased (~1.4x) with TrkB phosphorylation (~1.6x) in hippocampus, alongside improved conditioned avoidance responses. ### Monoaminergic modulation (dopamine/serotonin) *Verdict:* Plausible, animal-only Semax potentiated extracellular dopamine release after D-amphetamine administration in rat striatum, and is described as activating dopaminergic and serotonergic brain systems. In neurotoxin models, daily intranasal Semax (0.2 mg/kg) reduced severity of MPTP-induced behavioural disturbances, attributed to dopaminergic modulation and neurotrophic action. ### Nitric oxide, mitochondrial protection, and cellular stress *Verdict:* Mechanistic anchor in injury models In an incomplete global ischaemia model, Semax prevented enhanced nitric oxide generation in cerebral cortex and restored neurological function. At the cellular level, Semax (100 uM) delayed calcium dysregulation and mitochondrial membrane potential loss in cultured cerebellar granule cells under glutamate neurotoxicity and improved survival by ~30%. ### Gene-expression modulation (omics evidence) *Verdict:* Context-dependent, misinterpreted in marketing In permanent MCAO, a genome-wide microarray reported 96 genes altered at 3h and 68 at 24h, with immune-system genes representing >50% of modulated genes. In transient MCAO, RNA-Seq found 394 differentially expressed genes at 24h (FC>1.5, Padj<0.05). Protein-level follow-up showed reduced MMP-9, c-Fos, and JNK with increased CREB activation, consistent with reduced injury/inflammation signalling. ## Animal Studies | Domain | Species | Dose | Outcome | Limitation | | --- | --- | --- | --- | --- | | Neurotrophin binding and BDNF | Rat | Intranasal 50 & 250 ug/kg, single dose | Saturable binding (KD ~2.4 nM); BDNF increased in basal forebrain but not cerebellum | Rat tissue; binding site identity unclear; short timeframe (~3h assessment). | | Hippocampal BDNF/TrkB and learning | Rat | Intranasal 50 ug/kg, single dose | BDNF protein ~1.4x increase, TrkB phosphorylation ~1.6x increase, improved conditioned avoidance | Acute effects only; animal learning task does not equal human cognition claims. | | Neurotrophin gene expression | Rat | Intranasal 50 ug/kg, 1h exposure | Rapid, region-specific NGF/BDNF transcription changes in hippocampus and brainstem | Short duration; mRNA only; mixed directionality (NGF decreased in frontal cortex). | | Focal cortical infarct and memory | Rat | Intranasal ~250 ug/kg/day, 6 days | Reduced cortical infarct volume and improved passive avoidance retention after photothrombotic injury | Limited abstract detail; translational gap to clinical stroke outcomes. | | Ischaemia-reperfusion transcriptomics | Rat | IP 100 ug/kg post-occlusion + 1.5h + 5h after reperfusion | Reduced MMP-9, c-Fos, JNK; increased CREB at 24h post-tMCAO | Rodent model; targeted protein selection; clinical relevance uncertain. | | Transcriptome modulation (pMCAO) | Rat | Not fully extractable (gene-expression focus) | 96 DEGs at 3h, 68 at 24h; immune/chemokine/immunoglobulin genes dominate (>50%) | Gene modulation is injury-context specific; not a general enhancement claim. | | Transcriptome modulation (tMCAO) | Rat | Not fully extractable (gene-expression focus) | 394 DEGs at 24h (FC>1.5, Padj<0.05); suppressed inflammatory genes; activated neurotransmission genes | Small n typical for RNA-Seq (n=3/group); model-specific. | | Dopaminergic injury (MPTP) | Rat | Intranasal 0.2 mg/kg daily | Reduced severity of MPTP-induced behavioural disturbances | Neurotoxin model does not equal human PD treatment; behavioural endpoints only. | | Stress-gut axis and microbiota | Rat | IP 5-450 ug/kg, 12-15 min pre-stress | 50 & 150 ug/kg prevented stress-induced dysbiosis patterns during chronic restraint stress | Not a human gut-health claim; mechanistic attribution speculative. | | Early-life stress and metabolic effects | Rat | Intranasal 50 ug/kg daily, postnatal day 15-28 | Reduced negative effects of neonatal isolation stress on weight/metabolic dysfunction; normalised corticosterone | Early-life rodent stress model; not weight-loss drug evidence. | ## Human Studies ### Acute ischaemic stroke clinical study **Type:** Clinical study vs conventional therapy control **Participants:** 30 Semax vs 80 controls **Dose:** 12 mg (moderate) and 18 mg (severe) daily; 5-10 days **Outcome:** Faster regression of neurological deficits, especially motor; EEG/evoked potential monitoring included **Limitations:** Not clearly randomised/blinded; control not placebo; older study; Russian-language; endpoints/analysis detail limited in abstract. ### Post-stroke rehabilitation with BDNF monitoring **Type:** Clinical trial with subgroups by rehab timing **Participants:** 110 patients **Dose:** 6000 ug/day for 10 days, 2 courses with 20-day interval **Outcome:** Plasma BDNF increased and remained high; higher BDNF + Semax associated with better Barthel index and motor performance **Limitations:** Not a hard clinical endpoint trial (e.g., mortality/disability at 90 days); design details limited; Russian-language; causality confounding possible. ### Optic nerve disease / partial atrophy **Type:** Comparative clinical groups **Participants:** Not stated in abstract **Dose:** Intranasal drops vs endonasal electrophoresis vs control **Outcome:** Improvements in visual acuity, visual field, and electrophysiology measures reported **Limitations:** Non-English; unclear randomisation/blinding; sample size not in abstract; adjunctive therapy confounds. ### Healthy volunteer resting-state fMRI **Type:** Placebo-controlled imaging study **Participants:** 14 Semax vs 10 placebo (24 total) **Dose:** Intranasal 1% Semax, scanned pre and 5/20 min post **Outcome:** Greater volume of a default mode network rostral subcomponent vs controls **Limitations:** Imaging surrogate only; very small sample; no behavioural or cognitive endpoints. ## Hype vs Evidence | Claim | Social Media Implies | Evidence Supports | Verdict | | --- | --- | --- | --- | | Massively boosts BDNF, making you smarter | Guaranteed cognitive enhancement via BDNF increase | Semax increases BDNF/NGF mRNA in glial cultures and changes neurotrophin gene expression in rat brain; BDNF protein and TrkB activation changes in rat hippocampus. Human cognitive enhancement in healthy people is not established by robust trials. | Preclinical support; overgeneralised to humans | | Proven for stroke recovery | Established stroke treatment | Human studies exist but are small, often not placebo-controlled, largely Russian-language. Some report improved recovery dynamics and BDNF associations, but this is not equivalent to large, blinded, contemporary stroke RCT evidence. | Suggestive but not definitive | | Rewires hundreds of genes in your brain | Gene-therapy-like enhancement for healthy people | In rat stroke models, 68-96 DEGs in pMCAO microarray and 394 DEGs in tMCAO RNA-Seq at 24h (FC>1.5 with Padj criteria). This is injury-context-specific transcriptomic modulation, not broad beneficial genome rewiring in healthy humans. | Supported in injury models; misinterpreted | | Anti-inflammatory and neuroprotective in general | Universal brain protection | In tMCAO models, findings consistent with reduced inflammatory gene activation and markers (MMP-9/c-Fos/JNK) and increased CREB activation. Accurate to call this neuroprotective in specific rodent injury models, not universally neuroprotective. | Preclinically supported; general claims overstated | | Risk-free / no side effects | Safe enough for unsupervised self-use | Safety reporting in accessible abstracts is limited. FDA explicitly highlights immunogenicity, impurity concerns, and limited safety information for compounding contexts. Lack of reported adverse events does not equal proof of safety. | Misleading; safety is uncertain | | WADA-safe for athletes | Permitted in sport | WADA regulates peptide categories. This review could not confirm Semax's exact 2026 prohibited list status due to access limitations. Athletes should verify status via official lists and national anti-doping bodies. | Not verifiable; assume prohibited | ## Evidence Ratings | Domain | Score | Rationale | | --- | --- | --- | | Stroke/acute neuroprotection | 2/5 | Animal stroke models plus mechanistic omics are substantial; human studies exist but are limited, heterogeneous, and not clearly Western-standard RCT evidence. | | Cognition/nootropic (healthy enhancement) | 1/5 | Animal learning tasks and neurotrophin modulation exist; human evidence is largely imaging endpoints without robust cognitive outcomes. | | Mood/anxiety | 1/5 | Preclinical stress and neurotoxin models suggest behavioural modulation, but direct human evidence is not established. | | Safety in humans | 1/5 | Regulatory caution highlights limited safety information; clinical adverse-event reporting not extractable or robust in retrieved abstracts. | ## Safety & Regulatory ### Pharmacokinetics Human PK/ADME data were not identified in primary sources. Mechanistic metabolism work in rats shows Semax is degraded in blood/serum with prominent roles for bestatin-sensitive aminopeptidases (N-terminal cleavage) and a measurable contribution from ACE; Semax appears more stable than ACTH(4-10) against some enzymatic degradation pathways. A rat pharmacokinetics report describes tritium-labelled Semax penetrating brain and eyes after intranasal administration, but full quantitative PK parameters are not available. Marketing claims about rapid absorption and minute-range half-life exist on vendor sites but are not peer-reviewed primary PK evidence. ### Safety Statement Peer-reviewed abstracts rarely report adverse events or discontinuation rates in sufficient detail to quantify risk. Preclinical work shows biological activity at a range of doses and routes (intranasal, intraperitoneal), but this is not equivalent to systematic toxicology, reproductive risk profiling, carcinogenicity assessment, or long-term neuropsychiatric safety surveillance. If a product is not sourced via a regulated pharmaceutical channel, identity, purity, and sterility cannot be assumed. ### Regulatory Points **U.S. FDA — Category 2 bulk drug substance** Explicitly cites potential significant safety risks for compounding: immunogenicity risk for certain routes, aggregation and peptide-related impurity complexity, and limited safety information for proposed routes. The agency considers the available safety dossier inadequate for widespread compounded use. Source: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks **EMA — No marketing authorisation identified** No EMA marketing authorisation evidence was identified. Any EU clinical use claims should be treated as non-authorised and non-standard. Source: https://www.ema.europa.eu/ **WADA — Peptide category regulated** WADA's Prohibited List regulates peptide hormones and growth factors. This review could not reliably verify whether Semax is named in the 2026 document. Athletes should consult the current WADA list directly via official channels and national anti-doping agencies. Source: https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list ## Open Questions / Unknowns - No large, preregistered, blinded human clinical trials for cognitive enhancement in healthy people. - No robust human pharmacokinetics (PK/ADME) data in the public English-language literature; animal PK does not bridge this gap. - No comprehensive adverse-event profile; systematic toxicology, reproductive risk, and long-term neuropsychiatric safety data are missing. - Dose-exposure understanding is a major gap: animal studies span intranasal and intraperitoneal routes across wide ug/kg ranges, while human studies report mg-range daily totals without human PK bridging. - Which transcriptomic signals predict functional outcomes vs epiphenomena is unresolved, and whether omics effects replicate across labs and species. - AMPK and NRF2 pathway activation claims could not be confirmed from primary sources and should be treated as unsupported marketing add-ons. ## Frequently Asked Questions ### Does Semax boost BDNF and make you smarter? Semax can increase BDNF and NGF mRNA in rat brain regions and glial cultures, and BDNF protein and TrkB activation have been measured in rat hippocampus. However, human cognitive enhancement in healthy people is not established by robust clinical trials. The leap from rodent neurotrophin changes to guaranteed human intelligence gains is not supported. ### Is Semax proven for stroke recovery? Human studies exist, including small clinical studies in acute ischaemic stroke and post-stroke rehabilitation showing improved neurological recovery dynamics and associations with increased plasma BDNF. However, these are small, often not clearly placebo-controlled, frequently Russian-language, and do not represent large, blinded, contemporary stroke RCT evidence. ### Is Semax safe? Safety is uncertain. Peer-reviewed abstracts rarely report adverse events in sufficient detail. The U.S. FDA flags Semax as Category 2 with potential significant safety risks for compounding, citing immunogenicity risk, aggregation and peptide-related impurity complexity, and limited safety information for proposed routes. ### What are the side effects of Semax? A comprehensive side effect profile has not been established in English-language peer-reviewed literature. Preclinical work shows biological activity at various doses and routes, but systematic toxicology, reproductive risk profiling, and long-term neuropsychiatric safety surveillance data are not available in the public record. ### Does Semax rewire your genes? In rat stroke models, Semax alters dozens to hundreds of differentially expressed genes (68-96 in permanent MCAO; 394 in transient MCAO at 24h). This is injury-context-specific transcriptomic modulation in rodents, not evidence of broad beneficial genome rewiring in healthy humans. ### Is Semax legal? Semax is not authorised as a medicine by major Western regulators. The U.S. FDA classifies it as a Category 2 bulk drug substance with cited safety concerns for compounding. WADA regulates peptide categories. Athletes should verify status via official prohibited lists and national anti-doping bodies. ### How does Semax work? The clearest mechanistic evidence involves neurotrophin modulation (BDNF/NGF expression) via saturable binding sites in basal forebrain, monoaminergic system modulation (dopamine and serotonin), and anti-nitrosative/mitochondrial protection under injury conditions. Effects appear most consistent in acute injury/stress paradigms rather than baseline enhancement. ## References 1. **Saturable binding sites in rat basal forebrain membranes** — Journal of Neurochemistry — 2006 Tritiated Semax binding study demonstrating Ca2+-dependent, saturable binding with KD ~2.4 nM and BMAX ~33.5 fmol/mg protein https://pubmed.ncbi.nlm.nih.gov/16996037/ 2. **Hippocampal BDNF/TrkB activation and conditioned avoidance** — Neuroscience — 2008 Single intranasal dose (50 ug/kg) increased BDNF protein (~1.4x) and TrkB phosphorylation (~1.6x) in rat hippocampus with behavioural changes https://pubmed.ncbi.nlm.nih.gov/18239779/ 3. **Region-specific NGF and BDNF gene expression changes** — Doklady Biological Sciences — 2006 Rapid region-specific changes in neurotrophin mRNA after single intranasal Semax (50 ug/kg): increases in hippocampus, decreases in frontal cortex for NGF https://pubmed.ncbi.nlm.nih.gov/16635254/ 4. **NGF/BDNF mRNA induction in basal forebrain glia** — Neuroscience Letters — 2001 Semax increased BDNF mRNA ~8-fold and NGF mRNA ~5-fold at ~30 min peak in newborn rat basal forebrain glial cultures https://pubmed.ncbi.nlm.nih.gov/11457573/ 5. **Dopaminergic and serotonergic brain system activation** — Pharmacology Biochemistry and Behavior — 2001 Semax potentiated extracellular dopamine release after D-amphetamine and activates dopaminergic and serotonergic brain systems in rats https://pubmed.ncbi.nlm.nih.gov/11517472/ 6. **MPTP neurotoxin model: behavioural protection** — Bulletin of Experimental Biology and Medicine — 2007 Daily intranasal Semax (0.2 mg/kg) reduced severity of MPTP-induced behavioural disturbances attributed to dopaminergic modulation https://pubmed.ncbi.nlm.nih.gov/17353092/ 7. **Nitric oxide prevention in global ischaemia model** — Neuroscience and Behavioral Physiology — 2000 Semax prevented enhanced NO generation in cerebral cortex and restored neurological function in incomplete global ischaemia https://pubmed.ncbi.nlm.nih.gov/10763109/ 8. **Mitochondrial protection in glutamate neurotoxicity** — Regulatory Peptides — 2004 Semax (100 uM) delayed calcium dysregulation and mitochondrial membrane potential loss in cerebellar granule cells under glutamate neurotoxicity; ~30% improved survival https://pubmed.ncbi.nlm.nih.gov/15341218/ 9. **Genome-wide microarray in permanent MCAO** — BMC Genomics — 2014 Illumina RatRef-12 microarray (22,226 genes); 96 DEGs at 3h and 68 at 24h; immune-system genes >50% of Semax-modulated genes https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-15-228 10. **RNA-Seq analysis in transient MCAO model** — BMC Neuroscience — 2020 394 differentially expressed genes at 24h after tMCAO (FC>1.5, Padj<0.05); suppressed inflammatory genes and activated neurotransmission genes https://pmc.ncbi.nlm.nih.gov/articles/PMC7350263/ 11. **Post-ischaemic protein changes (MMP-9, CREB, JNK)** — Molecular Neurobiology — 2021 IP Semax 100 ug/kg post-occlusion: downregulated MMP-9, c-Fos, JNK; upregulated CREB in subcortical structures at 24h https://pmc.ncbi.nlm.nih.gov/articles/PMC8226508/ 12. **Focal cortical ischaemia: infarct volume and memory** — Brain Research — 1991 Intranasal Semax (~250 ug/kg/day, 6 days) reduced cortical infarct volume and improved passive avoidance retention in photothrombotic model https://pubmed.ncbi.nlm.nih.gov/1851003/ 13. **Enkephalin-degrading enzyme inhibition** — Bioorganic Chemistry — 2018 Semax inhibited enkephalin-degrading enzymes in human serum (IC50 ~10 uM) more potently than some comparator inhibitors https://pubmed.ncbi.nlm.nih.gov/30225715/ 14. **Amyloid-beta copper complex interaction** — International Journal of Molecular Sciences — 2022 Semax reduced amyloid-beta:Cu2+ complex formation and altered aggregation kinetics in artificial membrane models https://pmc.ncbi.nlm.nih.gov/articles/PMC8855339/ 15. **Semax enzymatic degradation in rat blood/serum** — Pharmaceutical Research — 1993 N-terminal cleavage via aminopeptidases and ACE contribution; Semax more stable than ACTH(4-10) against some pathways https://pubmed.ncbi.nlm.nih.gov/8392718/ 16. **Acute ischaemic stroke clinical study** — Zhurnal Nevrologii i Psikhiatrii (Russian) — 1997 30 Semax vs 80 controls; doses 12 mg (moderate) and 18 mg (severe) daily for 5-10 days; faster regression of neurological deficits https://pubmed.ncbi.nlm.nih.gov/19779827/ 17. **Post-stroke rehabilitation and BDNF monitoring** — Human Physiology — 2012 110 patients; 6000 ug/day for 10 days (2 courses); plasma BDNF increased and associated with better Barthel index dynamics https://pubmed.ncbi.nlm.nih.gov/22708068/ 18. **Optic nerve disease treatment** — Vestnik Oftalmologii (Russian) — 2004 Comparative clinical groups: intranasal drops vs endonasal electrophoresis vs control; improvements in visual acuity and electrophysiology https://pubmed.ncbi.nlm.nih.gov/15341218/ 19. **Healthy volunteer resting-state fMRI study** — Human Brain Mapping — 2020 14 Semax vs 10 placebo; intranasal 1% Semax; greater DMN rostral subcomponent volume at 5/20 min post-administration https://pubmed.ncbi.nlm.nih.gov/32737723/ 20. **Chronic restraint stress and colon microbiota** — Molecular Biology — 2022 IP 50 & 150 ug/kg prevented stress-induced dysbiosis patterns in rats under chronic restraint stress https://pubmed.ncbi.nlm.nih.gov/35080861/ 21. **Neonatal isolation stress and metabolic effects** — Neuropeptides — 2019 Intranasal 50 ug/kg daily postnatal day 15-28; reduced negative effects of neonatal stress on weight and normalised corticosterone https://pubmed.ncbi.nlm.nih.gov/29798983/